1. Safety, Tolerance, and Efficacy of Extended-Release Niacin Monotherapy for Treating Dyslipidemia Risks in Persons With Chronic Tetraplegia: A Randomized Multicenter Controlled Trial 
Mark S. Nash, PhD, John E. Lewis, PhD, Trevor A. Dyson-Hudson, MD, Yaga Szlachcic, MD, Florence Yee, PharmD, Armando J. Mendez, PhD, Ann M. Spungen, EdD, William A. Bauman, MD 
Archives of Physical Medicine and Rehabilitation 
Volume 92, Issue 3, Pages (March 2011)
DOI: /j.apmr
Copyright © 2011 American Congress of Rehabilitation Medicine Terms and Conditions

2. Fig 1
Consolidated Standards of Reporting Trials (CONSORT) flow diagram.
Archives of Physical Medicine and Rehabilitation  , DOI: ( /j.apmr )
Copyright © 2011 American Congress of Rehabilitation Medicine Terms and Conditions

3. Fig 2
Effects of extended-release niacin (ER-N) and placebo on (A) UA, (B) alanine transaminase, (C) aspartate transaminase, (D) alkaline phosphatase, and (E) total bilirubin levels.
Archives of Physical Medicine and Rehabilitation  , DOI: ( /j.apmr )
Copyright © 2011 American Congress of Rehabilitation Medicine Terms and Conditions

4. Fig 3
Effects of extended-release niacin (ER-N) and placebo on (A) fasting glycemia and (B) HbA1c level.
Archives of Physical Medicine and Rehabilitation  , DOI: ( /j.apmr )
Copyright © 2011 American Congress of Rehabilitation Medicine Terms and Conditions

5. Fig 4
Frequencies of (A) flushing and (B) insomnia and intensities of (C) flushing and (D) insomnia during extended-release niacin (ER-N) monotherapy.
Archives of Physical Medicine and Rehabilitation  , DOI: ( /j.apmr )
Copyright © 2011 American Congress of Rehabilitation Medicine Terms and Conditions

6. Fig 5
Effects of extended-release niacin (ER-N) and placebo on levels of (A) HDL-C, (B) LDL-C, (C) TC, (D) TG, and (E) TC/HDL-C and (F) LDL-C/HDL-C ratios (global risk ratios).
Archives of Physical Medicine and Rehabilitation  , DOI: ( /j.apmr )
Copyright © 2011 American Congress of Rehabilitation Medicine Terms and Conditions

7. Fig 6
Extended-release niacin dose-dependent changes in HDL-C, LDL-C, and TC levels. *P<.05 between baseline and each drug treatment; each bar represents the mean ± SEM value.
Archives of Physical Medicine and Rehabilitation  , DOI: ( /j.apmr )
Copyright © 2011 American Congress of Rehabilitation Medicine Terms and Conditions